Full Dataset & Comprehensive Report

R4IH Research Module #2: Benchmarking QALY gains by novel medicine, by country

This page provides access to the complete dataset and comprehensive report for the R4IH Research Module #2, which focuses on benchmarking Quality-Adjusted Life Year (QALY) gains across novel medicines by country.

Dataset Overview

The complete dataset includes detailed information on 43 novel medicines approved by the European Medicines Agency (EMA) in 2024, with comprehensive analysis of their expected health impacts measured in Quality-Adjusted Life Years (QALYs).

What's Included in the Full Dataset

Complete list of all 43 novel medicines with their therapeutic areas
Per-patient incremental QALY gains for each medicine
Patient population estimates by country
Total population-level QALY gains
Comparative analysis across therapeutic areas
Methodological details and assumptions

Sample Data Preview

Medicine	Therapeutic Area	Per-Patient QALY Gain	NL Patient Population	Total QALY Gain (NL)
Capivasertib	Breast Cancer	0.54	629	340
Medicine B	Rare Disease	2.87	42	121
Medicine C	Diabetes	0.18	2,450	441
Medicine D	Oncology	1.24	185	229
Medicine E	Cardiovascular	0.35	1,840	644

Download Resources

The following resources are available for download:

Full Dataset (Excel)

Complete dataset with all medicines and countries analyzed.

Download Dataset

Comprehensive Report (PDF)

Detailed methodology, findings, and implications for investors.

Download Report

Methodology Notes

The QALY gains in this dataset are calculated based on clinical trial data, health technology assessments, and expert consensus. The dataset represents the incremental health benefit of each medicine compared to the standard of care at the time of approval.

For investor use, these figures can help quantify the health impact of portfolio companies and inform investment decisions that optimize both financial returns and health outcomes.

← Back to Home